MTOR and alpha thalassemia spectrum: One of the earliest studies to conduct the full-exome sequencing of well-differentiated GEP-NETs revealed three distinct molecular profiles/pathways enriched with 16 unique gene alterations: the MEN1 pathway, the death-domain associated protein (DAXX)/alpha thalassemia/mental retardation syndrome X-lined (ATRX) pathway (the mammalian target of rapamycin (mTOR)), and the vascular endothelial growth factor (VEGF) pathway [50].